UPLC-MS/MS method for the identification of recombinant human erythropoietin analogues in horse plasma and urine

Chromatographia

Volumn 74, Issue 7-8, 2011, Pages 593-608

  Scarth, James P ^a   Seibert, Cathrin ^a   Brown, Pamela R ^a   Teale, Phil ^a   Beamon, Gavin J ^a   Pearce, Clive M ^a   Sams, Richard A ^a  

^a LGC   (United Kingdom)

Author keywords

Column liquid chromatography; Erythropoietin; Horse; Human; Plasma; Urine

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; DEGLYCOSYLATION; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG URINE LEVEL; HORSE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 80054951959     PISSN: 00095893     EISSN: 16121112     Source Type: Journal    
DOI: 10.1007/s10337-011-2119-y     Document Type: Article

References (32)

1. C Reichel G Gmeiner 2010 Erythropoietin and analogues Handb Exp Pharmacol 195 251 294 10.1007/978-3-540-79088-4-12 1:CAS:528:DC%2BC3cXnvFWnu7g%3D
2. McKeever KH, Agans JM, Geiser S, Lorimer PJ, Maylin GA (2006) Low dose exogenous erythropoietin elicits an ergogenic effect in standardbred horses. Equine Vet J Suppl 36:233-238
3. P Jaussaud M Audran RL Gareau A Souillard I Chavanet 1994 Kinetics and haematological effects of erythropoietin in horses Vet Res 25 6 568 573 1:CAS:528:DyaK2MXivFWjtL4%3D (Pubitemid 24369508)
4. C Cooper W Sears D Bienzle 2005 Reticulocyte changes after experimental anemia and erythropoietin treatment of horses J Appl Physiol 99 3 915 921 10.1152/japplphysiol.00438.2005 1:CAS:528:DC%2BD2MXhtVChu7jN (Pubitemid 41214503)
5. SMR Stanley A Poljak 2003 Matrix-assisted laser-desorption time-of flight ionisation and high-performance liquid chromatography-electrospray ionisation mass spectral analyses of two glycosylated recombinant epoetins J Chromatogr B Anal Technol Biomed Life Sci 785 2 205 218 10.1016/S1570-0232(02)00824-3 1:CAS:528:DC%2BD3sXmtVaksb0%3D (Pubitemid 36126160)
6. JC Egrie JK Browne 2001 Development and characterization of novel erythropoiesis stimulating protein (NESP) Br J Cancer 84 suppl 1 3 10 10.1054/bjoc.2001.1746 1:CAS:528:DC%2BD3MXktF2gt7g%3D (Pubitemid 32453429)
7. A Besarab MO Salifu NM Lunde V Bansal S Fishbane FC Dougherty U Beyer 2007 Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicentre, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease Clin Ther 29 4 626 639 10.1016/j.clinthera.2007.04.014 1:CAS:528:DC%2BD2sXmvVWnu78%3D (Pubitemid 47018271)
8. Association of Racing Commissioners International, Inc. (ARCI) (2009) Uniform classification guidelines for foreign substances and recommended penalties and model rule. http://www.arci.com/modelrules.html. Accessed 20th April 2011
9. Federation Equestre Internationale (FEI) (2010) Prohibited substances list. http://www.feicleansport.org/ProhibitedSubstancesList-Jan2010.pdf. Accessed 20th April 2011
10. British Horseracing Authority (BHA) (2010) Rules of racing: schedule 3-prohibited substances. http://rules.britishhorseracing.com. Accessed 20th April 2011
11. World Anti-Doping Agency (WADA) Questions and answers on EPO detection. http://www.wada-ama.org/en/Resources/Q-and-A/Q-A-EPO-Detection/. Accessed 19th April 2011
12. The 2011 Prohibited List International Standard (the World Anti-Doping Code) 2011 World Anti-Doping Agency, Clause S2 (2010) http://www.wada-ama.org/ Documents/World-Anti-Doping-Program/WADP-Prohibited-list/To-be-effective/ WADA-Prohibited-List-2011-EN.pdf. Accessed 1st June 2011
13. F Lasne L Martin N Crepin J De Ceaurriz 2002 Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones Anal Biochem 311 2 119 126 10.1016/S0003-2697(02)00407-4 1:CAS:528:DC%2BD38Xps1Wit7Y%3D (Pubitemid 35463470)
14. M Kohler C Ayotte P Desharnais U Flenker S Lüdke M Thevis E Völker-Schänzer W Schänzer 2008 Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels Int J Sports Med 29 1 1 6 10.1055/s-2007-989369 1:CAS:528: DC%2BD1cXjtVKktLw%3D (Pubitemid 351183231)
15. F Lasne L Martin JA Martin J de Ceaurriz 2009 Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control Haematologica 94 6 888 890 10.3324/haematol.2009.006809 1:CAS:528: DC%2BD1MXovFeis7w%3D
16. G Gmeiner C Reichel R Kulovics V Scheiblhofer 2010 Defending Dynepo detection Drug Test Anal 2 11-12 526 532 10.1002/dta.230 1:CAS:528: DC%2BC3MXit1CksQ%3D%3D
17. M Lönnberg Y Dehnes M Drevin M Garle S Lamon N Leuenberger T Quach J Carlsson 2010 Rapid affinity purification of erythropoietin from biological samples using disposable monoliths J Chromatogr A 1217 45 7031 7037 10.1016/j.chroma.2010.09.034
18. S Lamon J Boccard PE Sottas N Glatz G Wuerzner N Robinson M Saugy 2010 IEF pattern classification-derived criteria for the identification of epoetin-delta in urine Electrophoresis 31 12 1918 1924 10.1002/elps.200900645 1:CAS:528:DC%2BC3cXnvFSis7s%3D
19. Y Dehnes P Hemmersbach 2011 Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parameters Drug Test Anal 3 5 291 299 10.1002/dta.270 1:CAS:528:DC%2BC3MXmsVeqtbs%3D
20. Roberts J, Brown P, Cade S, Faustino-Kemp J, Lasne F, Williams B, Houghton E (2003) Evaluation of commercial ELISA kits to detect the administration of recombinant human erythropoietin (rHuEPO) to horses. In: Proceedings of the 14th international conference of racing analysts and veterinarians, Orlando, pp 234-242
21. Roberts J, Basgallop N, Brown P, Fastino-Kemp J (2005) Secondary and confirmatory analytical techniques to detect recombinant human erythropoietin (rHuEPO) in equine samples. In: Proceedings of the 15th international conference of racing analysts and veterinarians, Dubai, pp 188-195
22. F Lasne M-A Popot E Varlet-Marie L Martin J Martin Y Bonnaire J Audran J De Ceaurriz 2005 Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse J Anal Toxicol 29 8 835 837 1:CAS:528:DC%2BD2MXht1CqsLbI (Pubitemid 41803387)
23. DH Catlin GA Maylin S Benchaar SM Neades MS Timmon KH McKeever 2009 Detection of pegylated epoetin β in horse plasma after intravenous administration Comp Exerc Physiol 6 3 105 108 10.1017/S1755254009990171
24. F Guan CE Uboh LR Soma E Birks J Chen J Mitchell Y You J Rudy F Xu X Li G Mbuy 2007 LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin α in equine plasma Anal Chem 79 12 4627 4635 10.1021/ac070135o 1:CAS:528:DC%2BD2sXlt1WhtLs%3D (Pubitemid 46999580)
25. F Guan CE Uboh LR Soma E Birks J Chen W You J Rudy X Li 2008 Differentiation and identification of recombinant human erythropoietin and darbepoetin alfa in equine plasma by LC-MS/MS for doping control Anal Chem 80 10 3811 3817 10.1021/ac800054t 1:CAS:528:DC%2BD1cXktFSgsr0%3D (Pubitemid 351705886)
26. F Guan CE Uboh LR Soma G Maylin Z Jiang J Chen 2010 Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control Anal Chem 82 21 9074 9081 10.1021/ac102031w 1:CAS:528:DC%2BC3cXht12jtbrI
27. NH Yu ENM Ho TSM Wan ASY Wong 2010 Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry Anal Bioanal Chem 396 7 2513 2521 10.1007/s00216-010-3455-8 1:CAS:528: DC%2BC3cXhslOksbo%3D
28. Y Chang GM Maylin G Matsumoto SM Neades DH Catlin 2011 Screen and confirmation of PEG-epoetin β in equine plasma Drug Test Anal 3 1 68 73 10.1002/dta.212 1:CAS:528:DC%2BC3MXot1OhsQ%3D%3D
29. C Barton RG Kay 2008 Protein analysis using proteotypic peptides and LC-MS: choosing the right chromatographic separation for optimal coverage or throughput Chromatogr Today 1 11 14
30. L Bailly-Chouriberry F Noguier L Manchon D Piquemal P Garcia M-A Popot Y Bonnaire 2010 Blood cells RNA biomarkers as a first long-term detection strategy for EPO abuse in horseracing Drug Test Anal 2 7 339 345 10.1002/dta.146 1:CAS:528:DC%2BC3cXhtFKltrnP
31. Thevis M, Loo JA, Loo RR, Schänzer W (2007) Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing. Rapid Commun Mass Spectrom 21(3):297-304 (Pubitemid 46212540)
32. Association of Official racing Chemists (AORC) (2003) Guidelines for the minimum criteria for identification by chromatography and mass spectrometry. http://www.aorc-online.org/AORCMSCriteria.pdf. Accessed 20th April 2011